TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

Article Details

Citation
Copy to clipboard

Weeratna RD, Makinen SR, McCluskie MJ, Davis HL

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

Vaccine. 2005 Nov 1;23(45):5263-70. Epub 2005 Jul 18.

PubMed ID
16081189 [ View in PubMed
]
Abstract

TLR ligands that mimic pathogen associated molecular patterns and activate immune cells via Toll-like receptors (TLRs) are being developed for use in humans as therapy against a variety of diseases as well as vaccine adjuvants. These include imidazoquinoline compounds such as Imiquimod and Resiquimod (R-848) that bind to TLR7 and 8, as well as CpG oligodeoxynucleotides (CpG ODN) that bind to TLR9. This study was aimed at comparing CpG ODN and R-848 for their potential use as vaccine adjuvants and to determine whether there are additive or synergistic effects when they are used together. Using HBsAg as a model antigen in mice, we show CpG ODN to be superior to R-848 for augmenting both humoral and cell mediated immune responses.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
ResiquimodToll-like receptor 7ProteinHumans
Unknown
Not AvailableDetails
ResiquimodToll-like receptor 8ProteinHumans
Unknown
Not AvailableDetails